Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present at the 7th Plant Genomics & Gene Editing Congress

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company that uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, today announced that Kristi Snell, Ph.D., Yield10’s Chief Science Officer, will present today at the 7th Plant Genomics & Gene Editing Congress. The conference is being held November 4-5 in Raleigh, North Carolina.

At the 7th Plant Genomics & Gene Editing Congress, Dr. Snell will present a talk titled “Crop Trait Development: Target selection and validation using the GRAIN Platform.” In the presentation, Dr. Snell will discuss strategies the Yield10 team has employed to identify and edit novel gene targets using CRISPR genome editing to improve seed yield and oil content in oilseed crops.  Yield10 is using GRAIN 3.0 (“Gene Ranking Artificial Intelligence Network”), a unique gene discovery platform that uses metabolic insights obtained from metabolic modeling to mine genomics data and prioritize gene selection for traits. This platform allows the company to identify unique combinations of traits to increase oil content and seed yield. Performance traits, such as increased seed yield or oil content, can be combined with oil composition traits, such as high oleic and omega fatty acids, to develop high yielding, plant-based nutritional oils for use in food and feed products.   

“Over the last two years, we have expanded the capabilities of our GRAIN platform to identify unique genes to deliver performance traits such as increased yield. GRAIN 3.0 is unique in that it uses predicted changes in metabolism, that are likely necessary to enable a performance trait, to identify preferred genes to deliver the trait,” said Dr. Snell, Ph.D., Chief Science Officer of Yield10 Bioscience. “Deploying our performance traits in Camelina could transform the crop into an attractive platform for producing high value products such as specialty oils while providing growers in Canada and parts of the U.S. with an opportunity for crop diversification. We look forward to further advancing our GRAIN technology and deploying it to generate performance traits across additional crops.”

A copy of Dr. Snell’s slide deck is available on the Yield10 Bioscience investor relations website.

About Yield10 Bioscience

Yield10 Bioscience, Inc. is an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries to achieve step-change improvements in crop yield to enhance global food security and develop specialty crop products. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. The “Trait Factory” has two components: the “GRAIN” computational modeling platform, which is used to identify specific gene changes designed to improve crop performance, and the deployment of those changes into crops using genome-editing or traditional agricultural biotechnology approaches. The purpose of the “Trait Factory” is to engineer precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as canola, soybean, rice, wheat and corn. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada. 

For more information about the Company, please visit the website and follow the Company on Twitter and LinkedIn.

(YTEN-G)

Safe Harbor for Forward-Looking Statements 

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, that the GRAIN computational platform may be able to mine genomics data to identify novel gene targets and unique combinations of traits to increase oil content and seed yield, that the Company’s seed traits may achieve step-change improvements in crop yield, that deploying the Company’s performance traits in Camelina could transform the crop into an attractive platform for producing high value products such as specialty oils while providing growers in Canada and parts of the U.S. with an opportunity for crop diversification, and that the Company will enable the development of specialty crop products, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

Contacts: 

Yield10 Bioscience:Lynne H. Brum, [phone], [e-mail]

Investor Relations:  Bret Shapiro, [phone], [e-mail] Director, CORE IR

Media Inquiries: Eric Fischgrund, [e-mail] FischTank Marketing and PR